Objective
The Project will develop and commercialise the additive printing of cell-based analysis systems. The objective is to deliver consistent, scalable manufacturing of cell-based models used by multiple industry sectors to evaluate materials ranging from new drugs to healthcare products and functional foods. The target market is global and growing (CAGR 12%; estimated $4.2Bn in 2016). Additive printing will have positive disruptive impact, automating assay assembly and producing complex models needed by industry to improve the predictive value of cell-based analysis. Operational efficiencies and competitive pricing of printed cell products and services will win market share by making high-end analysis available to non-specialist users, whilst allowing wider integration of complex models into high-volume screening. The market advantage will be cost-effective testing and greater confidence in commercial decisions with strategic and financial impact.
The Phase 1 business plan will be built on market data, IP/technology audit and financial planning arising from 8 years’ successful ACS cell-based business. Phase 1 shall also prototype assays printed with iPSC-derived hepatocytes aimed at high-value hepatotoxicity testing; prototypes will be moved to TRL7, and in Phase 2 to market-ready TRL9 with client-reactive design aided by beta testing with opinion leaders. Technical innovation will use ACS core skills in human cell culture and build on commercial partnership with the UK National Centre for Additive Printing. Phase 2 will extend the technology platform to other cell models, expanding product range and commercial value. Post-project, these will be marketed and sold by expanding existing operations: initial hepatotoxicity sales alone are forecast at €0.6M one year post-launch (0.15% of global market). Market/sales extension to remote markets e.g. SE Asia will use JV companies or third-party distributors e.g. Japan. The Project requires 2.5 years and a budget of €2-2.5M.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
- engineering and technology mechanical engineering manufacturing engineering
- social sciences economics and business business and management business models
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.2.1.2. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
SME-1 - SME instrument phase 1
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-SMEInst-2014-2015
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
KA6 5HW Ayr
United Kingdom
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.